Studies oxidative stress and the Nrf2 response in early polycystic kidney disease
Studies cell stress and possible markers in young adults with early polycystic kidney disease.
Plain-language title generated from the registry record
Registry title: Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Key facts
- Where
- Rochester, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 30 years old?
Source: NCT04344769, who can take part
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT04344769
- Record updated
- 16 January 2026
- Original description
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.Read full original descriptionShow less
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
Inclusion: ADPKD (based on Ravine et al. criteria); Class 1 B-E according to our imaging classification; Male and female subjects 18 - 30 years of age, inclusive; Estimated GFR> 60 mL/min/m2 (CKD-EPI equation); Ability to provide written, informed consent; Male and female subjects 18 - 30 years of age, inclusive; Estimated GFR> 60 mL/min/m2 (CKD-EPI equation); Ability to provide written, informed consent.
Exclusion: Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis); Abnormal urinalysis suggestive of concomitant glomerular disease; Previous personal or family history of kidney disease; Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis); Abnormal urinalysis suggestive glomerular disease; Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics); Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics); Class 2 according to our imaging classification; Predicted urine protein excretion in urinalysis >1 g/24 hrs; Subjects having contraindications to, or interference with MRI assessments. [For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc]; Female subjects that are pregnant; Presence of proteinuria; Subjects having contraindications to, or interference with MRI assessments. [For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc]; Female subjects that are pregnant.